DOCSLIB.ORG

Cimetidine Tablets 200Mg, 400Mg and 800Mg

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cimetidine Tablets 200Mg, 400Mg and 800Mg PACKAGE LEAFLET: INFORMATION FOR THE USER Cimetidine Tablets 200mg, 400mg and 800mg [Cimetidine] Read all of this leaflet carefully before you start ! Are taking other medicines (see Section 'Other taking this medicine because it contains medicines and Cimetidine Tablets '). important information for you. ! Keep this leaflet. You may need to read it again. Other medicines and Cimetidine Tablets ! If you have any further questions, ask your doctor or pharmacist or nurse. Tell your doctor or pharmacist if you are taking, have ! This medicine has been prescribed for you only. recently taken or might take any other medicines. Do not pass it on to others. It may harm them, In particular tell your doctor if you are taking any of even if their signs of illness are the same as the following: yours. ! Anticoagulants to thin your blood e.g. warfarin ! If you get any side effects, talk to your doctor, or ! Anticonvulsants to prevent fits e.g. phenytoin pharmacist or nurse. This includes any possible ! Bronchodilators for breathing difficulties e.g. side effects not listed in this leaflet. See section 4. theophylline ! Anti-arrhythmics to slow heart rate e.g. lidocaine, What is in this leaflet: propranolol 1. What Cimetidine Tablets are and what they ! Antidepressants to treat anxiety e.g. diazepam are used for ! Immunosuppresants to prevent organ rejection 2. What you need to know before you take or rheumatism (e.g. ciclosporin) Cimetidine Tablets ! Medicines that cause a fall in blood cell count 3. How to take Cimetidine Tablets ! Antifungals used to treat fungal infections (e.g. 4. Possible side effects ketoconazole, itraconazole or 5. How to store Cimetidine Tablets posaconazole) 6. Contents of the pack and other information ! Antidiabetics to lower glucose levels in the blood (e.g. metformin 1. WHAT CIMETIDINE TABLETS ARE AND or glipizide) WHAT THEY ARE USED FOR ! Anti-cancer drugs for the treatment of cancer or tumors (e.g. carmustine, Cimetidine Tablets belong to a group of medicines fluorouracil, epirubicin, or therapies called H2-receptor antagonists which act to such as radiation) decrease the natural production of acid in the ! Strong pain killers (e.g. morphine) stomach. ! Antiretroviral drugs used to treat Cimetidine Tablets have been prescribed to treat any HIV/AIDS (e.g. atazanavir) of the following: ! Tacrolimus used to treat eczema ! Ulcers in the stomach (gastric ulcer) or in the ! Medicines to treat heart problems e.g. upper part of the intestine (duodenum ulcer) diltiazem, procainamide, metoprolol. ! Acid from the stomach escaping into the food pipe causing pain, inflammation and heartburn Pregnancy and breast-feeding (oesophageal reflux disease) ! Ask your doctor or pharmacist for advice if you are Excess acid in the stomach caused by a tumor in pregnant, planning on becoming pregnant or are the pancreas (Zollinger-Ellison syndrome) ! breast- feeding. The use of Cimetidine during Ulcers in the stomach or duodenum which may pregnancy and breast-feeding should be avoided be caused by non-steroidal anti-inflammatory unless considered essential by your doctor. drugs (NSAIDs), often used to reduce pain, fever and inflammation ! Various conditions where reduction of gastric Driving and using machines acid by cimetidine has been shown to be These tablets can cause some people to feel dizzy or beneficial e.g. drowsy. If you are affected do not drive or operate , Indigestion symptoms (e.g. stomach pain or machinery. discomfort, heartburn) , Meal-related upper abdominal pain 3. HOW TO TAKE CIMETIDINE TABLETS , To prevent stress ulcers from bleeding , To be given before general anaesthesia to prevent damage to the lungs caused by Always take Cimetidine Tablets exactly as your breathing in stomach fluids (acid aspiration) doctor has instructed you. You should check with , To improve absorption of food and reduce your doctor or pharmacist if you are unsure. fluid loss in short bowel syndrome , Reduction of breakdown of pancreatic The usual dosage is 400mg to 1600mg cimetidine enzyme supplements. per day. Take twice a day with breakfast and at bedtime or as directed by your doctor. 2. WHAT YOU NEED TO KNOW BEFORE YOU Do not take more then 2400mg cimetidine per day. TAKE CIMETIDINE TABLETS Do not take Cimetidine Tablets: Elderly: ! If you are hypersensitive (allergic) to cimetidine The normal adult dosage may be used unless you or any of the other ingredients of Cimetidine have kidney problems. Tablets (listed in section 6). Patients with duodenal or gastric ulceration: Warnings and precautions A single dose of 800mg at bedtime is recommended. Talk to your doctor, pharmacist or nurse before taking Although your doctor may recommend 200mg three Cimetidine Tablets if you: times a day with meals and 400mg at bedtime. ! Suffer or have suffered in the past from kidney disease ! Have a history of peptic ulcer, particularly if you Patients with oesophageal reflux disease: are taking a non-steroidal anti-inflammatory drug 400mg four times a day with meals and at bedtime is (NSAID) e.g. aspirin, ibuprofen, naproxen, recommended. diclofenac ! Are taking drugs or you have an illness that could Patients with Zollinger-Ellison syndrome: cause a fall in blood cell count ! Are middle aged or over, with new or recently 400mg four times a day with meals and at bedtime is changed indigestion symptoms (e.g stomach recommended. Higher doses may be given. pain or discomfort, heartburn), then other causes of your symptoms such as stomach cancer, should be excluded PENC 1520 Patients with acid aspiration: Very rare side effects (affects less than 1 user in A dose of 400mg can be given 90-120 minutes 10,000): before having a general anaesthetic or, in obstetric ! Pancytopenia - blood disorder with low number practice, at the start of labour. While there is still a of red and white blood cells and platelets risk of acid aspiration, a dose of up to 400mg may be ! Agranulocytosis - blood disorders with very low repeated at 4 hourly intervals, as required, up to the numbers of white blood cells usual daily maximum of 2.4g. ! Heart block - symptoms may include irregular heartbeats Prevention of bleeding from stress ulcers in seriously ! Inflammation of the pancreas - symptoms ill patients: include stomach and back pain, nausea and 200-400mg can be given every 4-6 hours. vomiting ! Hair loss -reversible after treatment has stopped Patients with kidney problems: ! Arthralgia - aching muscles and joints Doses may be reduced but your doctor will advise ! Galactorrhoea - leakage of a milky substance you on the amount to take. from the breasts ! Fever. If you take more Cimetidine Tablets than you should Reporting of side effects This medicine is to be taken at regular intervals, as If you get any side effects, talk to your doctor, determined by the physician. If you take too many pharmacist or nurse. This includes any possible side tablets by mistake contact your nearest hospital effects not listed in this leaflet. You can also report casualty department or tell your doctor immediately. side effects directly via the Yellow Card Scheme at: Take your tablet pack with you. www.mhra.gov.uk/yellowcard By reporting side effects you can help provide more If you stop taking Cimetidine Tablets information on the safety of this medicine. You may feel better after a few days, but you should keep taking your tablets until the prescribed course is 5. HOW TO STORE CIMETIDINE TABLETS finished. Your symptoms may come back if you stop your treatment too soon. Check the expiry date printed on the label or side of the box. Do not use after the expiry date stated on the If you forget to take Cimetidine Tablets label. If you have forgotten to take a dose, leave out that Do not store above 25°C. Store in the original dose completely. Take your next dose at the normal package. time. If you have trouble remembering to take the In case of any visible signs of deterioration, you tablets, tell your doctor or pharmacist. should discard the package. Medicines should not be disposed of via waste water 4. POSSIBLE SIDE EFFECTS or household waste. Ask your pharmacist how to dispose of medicines no longer required. These Like all medicines, this medicine can cause side measures help to protect the environment. effects, although not everyone gets them. Keep out of the sight and reach of children Allergic reactions may occur rarely, with symptoms such as rash, itching, swelling of the face, 6. CONTENTS OF THE PACK AND OTHER wheeziness, shortness of breath, tightness in the INFORMATION chest, fever, low blood pressure and feeling dizzy particularly when standing up. If any of these occur What Cimetidine Tablets contain: STOP taking the medicine and contact a doctor Cimetidine Tablets 200, 400 and 800mg contain immediately. the active substance cimetidine 200mg, 400mg or 800mg in each film-coated tablet respectively. Common side effects (affects 1 to 10 users in 100): The other ingredients are: Microcrystalline cellulose ! Headache (E460), povidone 30, sodium starch glycollate, ! Dizziness sodium lauryl sulphate, colloidal silicon dioxide, ! Diarrhoea magnesium stearate, hydroxypropyl methylcellulose ! Skin rashes (E464), polyethylene glycol, quinoline yellow ! Myalgia (muscle aches) aluminium lake (E104), indigo carmine aluminium ! Tiredness. lake (E132), titanium dioxide (E171) and iron oxide yellow (E172). Uncommon side effects (affects 1 to 10 users in 1,000): What Cimetidine Tablets look like and contents ! Leukopenia - decrease in the number of white of the pack blood cells Cimetidine Tablets 200mg are pale green, circular, ! Depression biconvex, film coated tablets, embossed with C1 on ! Confusion (usually in the elderly or seriously ill) one side. ! Hallucinations (hearing and seeing things that Cimetidine Tablets 400mg are pale green, oblong, are not there) film coated tablets, embossed with C2 on one side. ! Tachycardia (fast heartbeat) Cimetidine Tablets 800mg are pale green, oval, film ! Liver disorder (hepatitis) stomach and abdomen coated tablets, embossed with C3 on one side.
Load more

Recommended publications
  • Drug-Induced Sexual Dysfunction in Men and Women
    VOLUME 36 : NUMBER 2 : APRIL 2013 ARTICLE Drug-induced sexual dysfunction in men and women Helen M Conaglen whether the clinician is willing to ask about sexual Clinical psychologist and SUMMARY issues and does so in a sensitive way.7,8 Senior research fellow Many medical conditions and their treatments Patients on long-term medications may not be John V Conaglen aware that their sexual problems have developed Endocrinologist and contribute to sexual dysfunction. as a result of their treatment. Conversely some may Associate professor in Commonly implicated drugs include Medicine blame their drugs for sexual problems which are due Sexual Health Research Unit antihypertensives, antidepressants, to relationship difficulties or other stressors. Some Waikato Clinical School antipsychotics and antiandrogens. doctors consider that asking patients if they had Faculty of Medical and Understanding the potential for drug-induced noticed any sexual adverse effects from their drugs Health Sciences University of Auckland sexual problems and their negative impact may ‘suggest’ them to the patient, and possibly result on adherence to treatment will enable the in non-adherence. Patients attributing their sexual clinician to tailor treatments for the patient problems to their drugs are less likely to continue the Key words treatment even when necessary for their health.9 The antidepressants, and his or her partner. consultation should include discussion of the patient’s antihypertensives, Encouraging a discussion with the patient sexual issues so these can be considered in treatment antipsychotics, arousal, about sexual function and providing erectile dysfunction, decisions. hypoactive sexual desire strategies to manage the problem are critical disorder, male impotence, to good clinical care.
    [Show full text]
  • Dative Metabolism of Cortisol in Humans Kunihi
    臨 床 薬 理JPn J Clin Pharmacol Ther 18 (3) Sept 1987 509 Comparison of the Inhibitory Effects of Famotidine and Cimetidine on Hepatic Oxi- dative Metabolism of Cortisol in Humans Kunihiko MORITA* Hiroki KONISHI* Takeshi ONO* and Harumi SHIMAKAWA* (Receivedon Dec.19, 1986) * Hospital Pharmacy, Shiga Universityof Medical Science, Tsukinowa-cho,Seta, Ohtsu520-21, Japan The inhibitory effect of famotidine, a new H2-receptor antagonist, on hepatic oxidative metabolism of cortisol in six healthy volunteers was compared with that of cimetidine by monitoring the change in urinary 6ƒÀ-hydroxycortisol (6ƒÀ-OHF), an oxidative metabolite of cortisol. The ratio of 6ƒÀ-OHF to 17-hydroxycorticosteroids (17-OHCS) in urine was measured before, during, and after treatment with famotidine and cimetidine for 3 days in a cross-over study. The ratio was decreased by 25% -35% of the original level after 1-3 days of oral treatment with cimetidine (800 mg, b. i. d.). The reduction vanished within 2 days after the last dose of cimetidine. The ratio was not significantly changed during oral treatment with famotidine (40 mg, b. i. d.). These findings indicate that famotidine, in contrast to cimetidine, does not affect the hepatic oxidative metabolism of cortisol in man, and it is suggested that famotidine does not affect the hepatic drug-metabolizing capacity in humans. Key words: famotidine, cimetidine, H2-receptor antangonist, 6ƒÀ-hydroxycortisol, enzyme inhibition been shown to inhibit the hepatic elimination of a Introduction number of drugs coadministred.1-4) A number of Cimetidine, a histamine H2-receptor antagonist studies have demonstrated that this inhibitory widely used for the treatment of peptic ulcer, has action of cimetidine is based on its high affinity for cytochrome P-450 in hepatic microsomes *滋 賀医科大学医学部附属病院薬剤部 arising from imidazole and cyano groups.5-7) 〓520-21滋 賀県大津市瀬田月輪町 Ranitidine, an H2-receptor antagonist developed 510 hospital pharmacists, aged 24 to 35 years old (mean 28), participated in the study.
    [Show full text]
  • Auspar Attachment 1. Product Information for Mifepristone
    Attachment 1: Product information for AusPAR MS-2 Step mifepristone/misoprostol MS Health Pty Ltd PM-2013-01037-1-5 Final 13 October 2014. This Product Information was approved at the time this AusPAR was published. PRODUCT INFORMATION - MS-2 StepÔ It is very important that all patients receiving these medications are followed up by a medical practitioner, preferably the prescriber, to ensure that the medication has been effective. Even if no adverse events have occurred all patients must receive follow-up 14 to 21 days after taking mifepristone. Read the SPECIAL WARNINGS AND PRECAUTIONS FOR USE carefully. This document refers to the use of MS-2 StepÔ, which consists of Mifepristone Linepharma 200 mg tablet and GyMiso® misoprostol 200 microgram tablets in combination. These medicines are indicated in females of childbearing age for the medical termination of a developing intrauterine pregnancy, up to 63 days of gestation. The Mifepristone Linepharma 200 mg tablet component of this therapy is also used to treat another condition. For information about the treatment of the other condition, refer to the full Product Information for Mifepristone Linepharma 200 mg tablet individual product (AUST R 175671). NAME OF THE MEDICINE MS-2 StepÔ is a composite pack containing Mifepristone Linepharma 200 mg tablet and GyMiso® misoprostol 200 microgram tablets. Mifepristone Australian Approved Name (AAN): Mifepristone Chemical Structure: CH3 N CH 3 OH CH H CH3 3 H H O Molecular formula: C29H35NO2 Molecular weight: 429.6 Version:22May2014 [63days] Page 1 of 23 Attachment 1: Product information for AusPAR MS-2 Step mifepristone/misoprostol MS Health Pty Ltd PM-2013-01037-1-5 Final 13 October 2014.
    [Show full text]
  • 2021 Formulary List of Covered Prescription Drugs
    2021 Formulary List of covered prescription drugs This drug list applies to all Individual HMO products and the following Small Group HMO products: Sharp Platinum 90 Performance HMO, Sharp Platinum 90 Performance HMO AI-AN, Sharp Platinum 90 Premier HMO, Sharp Platinum 90 Premier HMO AI-AN, Sharp Gold 80 Performance HMO, Sharp Gold 80 Performance HMO AI-AN, Sharp Gold 80 Premier HMO, Sharp Gold 80 Premier HMO AI-AN, Sharp Silver 70 Performance HMO, Sharp Silver 70 Performance HMO AI-AN, Sharp Silver 70 Premier HMO, Sharp Silver 70 Premier HMO AI-AN, Sharp Silver 73 Performance HMO, Sharp Silver 73 Premier HMO, Sharp Silver 87 Performance HMO, Sharp Silver 87 Premier HMO, Sharp Silver 94 Performance HMO, Sharp Silver 94 Premier HMO, Sharp Bronze 60 Performance HMO, Sharp Bronze 60 Performance HMO AI-AN, Sharp Bronze 60 Premier HDHP HMO, Sharp Bronze 60 Premier HDHP HMO AI-AN, Sharp Minimum Coverage Performance HMO, Sharp $0 Cost Share Performance HMO AI-AN, Sharp $0 Cost Share Premier HMO AI-AN, Sharp Silver 70 Off Exchange Performance HMO, Sharp Silver 70 Off Exchange Premier HMO, Sharp Performance Platinum 90 HMO 0/15 + Child Dental, Sharp Premier Platinum 90 HMO 0/20 + Child Dental, Sharp Performance Gold 80 HMO 350 /25 + Child Dental, Sharp Premier Gold 80 HMO 250/35 + Child Dental, Sharp Performance Silver 70 HMO 2250/50 + Child Dental, Sharp Premier Silver 70 HMO 2250/55 + Child Dental, Sharp Premier Silver 70 HDHP HMO 2500/20% + Child Dental, Sharp Performance Bronze 60 HMO 6300/65 + Child Dental, Sharp Premier Bronze 60 HDHP HMO
    [Show full text]
  • Complete Inhibition of Food-Stimulated Gastric Acid Secretion by Combined Application of Pirenzepine and Ranitidine*
    Gut: first published as 10.1136/gut.22.7.542 on 1 July 1981. Downloaded from Gut, 1981, 22, 542-548 Complete inhibition of food-stimulated gastric acid secretion by combined application of pirenzepine and ranitidine* W LONDONG,t V LONDONG, C RUTHE, AND P WEIZERT From the Medizinische Klinik Innenstadt, University ofMunich, Munich, W Germany SUMMARY In a double-blind, placebo controlled and randomised secretory study the effectiveness of pirenzepine, ranitidine, and their combination was compared intraindividually in eight healthy subjects receiving intravenous bolus injections. Pirenzepine (0.15 mg/kg) plus ranitidine (0-6 mg/kg) suppressed peptone-stimulated gastric acid secretion from 69±11 to 2±0-4 mmol H+/3 h; the mean percentage inhibition was 97%. Postprandial gastrin was unaffected. There were only minor side-effects in a few experiments (reduction of salivation, brief blurring of vision), but no prolactin stimulation after ranitidine or ranitidine plus pirenzepine. The combined application of ranitidine and pirenzepine inhibited meal-stimulated acid secretion more effectively and produced fewer side-effects than the combination of cimetidine plus pirenzepine studied previously. The combined application ofclassical anticholinergics Methods and H2-receptor antagonists inhibits basal and http://gut.bmj.com/ stimulated gastric acid secretion in man more than Each subject had four tests which had to be carried either drug alone.' In double-blind, placebo con- out within a fortnight; the interval between two tests trolled and randomised investigations we have was at least three days. On separate days each subject demonstrated79 that combined intravenous bolus received pirenzepine, ranitidine, pirenzepine plus injections ofthe antimuscarinic drug pirenzepine with ranitidine, and placebo in random order by slow cimetidine suppressed peptone-stimulated acid out- intravenous bolus on a double-blind basis according put more effectively (on average by 90%) than either to a predetermined randomisation code.
    [Show full text]
  • These Highlights Do Not Include All the Information Needed to Use PRASTERA® Safely and Effectively
    PRASTERA- prasterone and ibuprofen Health Science Funding, LLC Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PRASTERA® safely and effectively. See full prescribing information for PRASTERA® . PRASTERA® prasterone oral softgels 200mg are for oral use only. Initial U.S. Approval INDICATIONS AND USAGE PRASTERA® prasterone 200 mg oral softgels is indicated in female patients with mild to moderate, active (SLEDAI ≥2) systemic lupus erythematosus (SLE) to restore serum 5-dehydroandrosterone sulfate to levels typical of women without SLE. In Phase III clinical trials in female patients with mild to moderate active SLE, prasterone 200 mg was associated with reduced risk of auto-immune flare, reduced risk of breast cancer and reduced risk of death from any cause. (§§1, 6.2, 6.4, 6.5) DOSAGE AND ADMINISTRATION The recommended dose is one (1) softgel daily. (§2) DOSAGE FORMS AND STRENGTHS 200mg oral softgel capsules supplied in a convenience package with ibuprofen oral tablets 400mg. (§3) CONTRAINDICATIONS Known hypersensitivity to any of its ingredients. (§4) Undiagnosed abnormal genital bleeding. (§4) Known, suspected or history of breast cancer. (§4, §6.5) History of, or known, deep vein thrombosis, pulmonary embolism, arterial thromboembolic disease (e.g., stroke, myocardial infarction). (§4) Hypercholesterolemia or ischemic heart disease. (§4, §7.2.4) Hepatic or renal impairment (pharmacokinetic data lacking). (§4, §7.2) Breast-feeding or known or suspected pregnancy.
    [Show full text]
  • 14 LETTERS to the EDITORS 565 EFFECT of CIMETIDINE on GONADAL FUNCTION in MAN We Were Interested to Read the Paper by Wang Et Al
    Br. J. clin. Pharmac. (1982), 14 LETTERS TO THE EDITORS 565 EFFECT OF CIMETIDINE ON GONADAL FUNCTION IN MAN We were interested to read the paper by Wang et al. dine being an antiandrogen in man and this is sup- (1982) which showed that treatment of male patients ported by the finding that cimetidine competes with suffering from duodenal ulcer with cimetidine was androgens for binding to androgen receptors in associated with a significant rise in serum testosterone human skin fibroblasts (Sultan et al., 1980) as it also levels. We are aware of four other published studies does in mouse kidney preparations (Funder & on this topic (including one cited by Wang et al., 1982 Mercer, 1979). (van Thiel et al., 1979)) in patients being treated for Since cimetidine but not ranitidine has this effect acid peptic disorders with cimetidine (Carlson et al., then it is not a function of H2-receptor blockade 1981; Peden et al., 1981; Spona et al., 1981). (Peden et al., 1981). The clinical relevance of this All of these studies showed that treatment with recently became apparent to us when we were cimetidine was associated with a modest rise in basal referred a 50 year old man who had received testosterone levels although this rise was statistically cimetidine 1g/day continuously for 18 months for a significant in only two of the papers (Peden et al., stomal ulcer. He had gynaecomastia and complained 1981; van Thiel et al., 1979). Two of the studies were of impotence. Measurements of serum prolactin, prospective and comparative. That of Carlson et al.
    [Show full text]
  • PACKAGE LEAFLET – INFORMATION for the USER Cimetidine
    PACKAGE LEAFLET – INFORMATION FOR THE USER Cimetidine 200mg Tablets Cimetidine 400mg Tablets Cimetidine 800mg Tablets (Cimetidine) Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. In this leaflet: 1. What Cimetidine tablets are and what they are used for 2. What you need to know before you take Cimetidine tablets 3. How to take Cimetidine tablets 4. Possible side effects 5. How to store Cimetidine tablets 6. Contents of the pack and other information 1. What Cimetidine tablets are and what they are used for Cimetidine belongs to a group of medicines called Histamine H2 receptor antagonists and is used as an anti-ulcer drug. It works by reducing the amount of acid in your stomach. Cimetidine is used to treat and relieve the following conditions: Ulcers in the stomach (gastric ulcer) and in upper part of the intestine (duodenum ulcer). Recurrent or stomac ulcers (ulcers that keep coming back or which have occurred following stomach surgery). Ulcers in the stomach or duodenum which may be caused by non-steroidal anti- inflammatory drugs (NSAIDs, often used to reduce pain, fever and inflammation) Acid from the stomach escaping into the food pipe causing pain, inflammation and heartburn (oesophageal reflux).
    [Show full text]
  • Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act
    Updated June 07, 2021 Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Three categories of bulk drug substances: • Category 1: Bulk Drug Substances Under Evaluation • Category 2: Bulk Drug Substances that Raise Significant Safety Risks • Category 3: Bulk Drug Substances Nominated Without Adequate Support Updates to Categories of Substances Nominated for the 503B Bulk Drug Substances List1 • Add the following entry to category 2 due to serious safety concerns of mutagenicity, cytotoxicity, and possible carcinogenicity when quinacrine hydrochloride is used for intrauterine administration for non- surgical female sterilization: 2,3 o Quinacrine Hydrochloride for intrauterine administration • Revision to category 1 for clarity: o Modify the entry for “Quinacrine Hydrochloride” to “Quinacrine Hydrochloride (except for intrauterine administration).” • Revision to category 1 to correct a substance name error: o Correct the error in the substance name “DHEA (dehydroepiandosterone)” to “DHEA (dehydroepiandrosterone).” 1 For the purposes of the substance names in the categories, hydrated forms of the substance are included in the scope of the substance name. 2 Quinacrine HCl was previously reviewed in 2016 as part of FDA’s consideration of this bulk drug substance for inclusion on the 503A Bulks List. As part of this review, the Division of Bone, Reproductive and Urologic Products (DBRUP), now the Division of Urology, Obstetrics and Gynecology (DUOG), evaluated the nomination of quinacrine for intrauterine administration for non-surgical female sterilization and recommended that quinacrine should not be included on the 503A Bulks List for this use. This recommendation was based on the lack of information on efficacy comparable to other available methods of female sterilization and serious safety concerns of mutagenicity, cytotoxicity and possible carcinogenicity in use of quinacrine for this indication and route of administration.
    [Show full text]
  • Study Protocol and Statistical Analysis Plan
    ECOG-ACRIN Operations Office – Boston Frontier Science 900 Commonwealth Avenue Boston, MA 02215 (617) 632-3610 Fax: (617) 632-2990 Randomization: (617) 632-2022 Group Chair: Robert L. Comis, M.D. and Mitchell Schnall, M.D. Jean MacDonald, Director of Research Operations Group Statistician: Robert Gray, Ph.D. and Constantine Gatsonis, Ph.D. Mary Steele, Director of Group Administration July 31, 2014 Martha Kruhm, MS RAC Head, Protocol and Information Office Quality Assurance Section CTEP, DCT, NCI 6130 Executive Blvd, EPN Room 7000 Bethesda, MD 20892 Dear Ms. Kruhm: Enclosed is Addendum #9 to E2809, Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy. The following revisions to E2809 protocol have been made in this addendum: Section Change 1. Cover Page Updated the version date. Inserted into the first and second bullet points the phrase "confirmed on 2. Section 6.1.4 two consecutive additional determinations taken at least 4 weeks apart," to more clearly define undetectable PSA. The following revisions to E2809 Informed Consent Document have been made in this addendum: Section Change 1. Cover Page Updated the version date. "What side effects or Updated the risk section language to correspond with the condensed 2. risks can I expect from risk lists format. being in the study?" "What side effects or 3. risks can I expect from Inserted condensed risk list for Bicalutamide. being in the study?" If you have any questions regarding this addendum, please contact [email protected] or 617-632-3610.
    [Show full text]
  • An Investigation Into the Effects and Possible
    AN INVESTIGATION INTO THE EFFECTS AND POSSIBLE MECHANISMS OF ACTION OF CIMETIDINE AND RANITIDINE ON THE SEXUAL BEHAVIOUR OF MALE RATS BY ROOPRAM BADRI Dip.Med.Tech. (Clin Path); Dip.Med.Tech. (Histopath) Submitted in part fulfilment of the requirements for the degree of Master of Medical Science in the Department of Pharmacology in the Faculty of Health Sciences at the University of Durban-Westville. Supervisor: Professor AL du Preez Joint-Supervisor: Mrs MJ du Preez Date Submitted: June 1985 ACKNOWLEDGEMENTS It is a special pleasure to thank Professor AL du Preez, Rector of Technikon, Natal, (former Head of Pharmacology Department, University of Durban-Westville), who conceived the idea for ' this investigation and offered excellent guidance and constructive criticisms during the course of this study. I am grateful to Mrs MJ du Preez for her encouragement and many valuable suggestions while supervising this research. My sincere thanks are extended to Professor AM Veltman for his kindness and constant encouragement; the late Mr RD Ramkisson for statistical assistance; Professor R Miller and the Pharmacology staff for their assistance in various ways; Mr S Baboolal for writing statistical programs; Mr AI Vawda for assistance with anti androgen studies; Miss I Venkatas for help on use of word processor: and to many colleagues at the University of Ourban-Westville for their generous help. My sincere appreciation goes to Mr HJ Klomfass, Natal Institute of Immunology, for assistance with techniques in ovariectomy and cardiac puncture; Or RH Scott (Department of Pathology), Addington Hospital, for assistance with histology of testes; Or RJ Norman (Department of Chemical Pathology), University of Natal Medical School, for radioimmunoassay of serum testosterone; Mr S Tejram and Mr P Naicker (Department of Medical Illustration), University of Natal Medical School, for photographic assistance.
    [Show full text]
  • Cimetidine | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Cimetidine This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Cimetidine Acid Reducer [OTC] Brand Names: Canada APO-Cimetidine; DOM-Cimetidine [DSC]; MYLAN-Cimetidine [DSC]; NOVO- Cimetine [DSC]; PMS-Cimetidine [DSC] What is this drug used for? It is used to treat or prevent GI (gastrointestinal) ulcers. It is used to treat gastroesophageal reflux disease (GERD; acid reflux). It is used to treat heartburn and sour stomach. It is used to treat syndromes caused by lots of stomach acid. It may be given to you for other reasons. Talk with the doctor. What do I need to tell my doctor BEFORE I take this drug? If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you are taking dofetilide. If you are breast-feeding. Do not breast-feed while you take this drug. Cimetidine 1/6 This is not a list of all drugs or health problems that interact with this drug. Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor.
    [Show full text]